Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/12/2026

Best Medication for Lowering Intraocular Pressure in Primary Open-Angle Glaucoma

Medication Selection Algorithm

  • The American Academy of Ophthalmology recommends prostaglandin analogs as the first-line treatment for lowering intraocular pressure in patients with primary open-angle glaucoma due to their superior efficacy, once-daily dosing, and favorable side effect profile 1, 2, 3
  • Prostaglandin analogs are the most efficacious at lowering IOP, with a 20-35% reduction, and have once-daily dosing that improves adherence 2, 4
  • Prostaglandin analogs are well-tolerated with minimal systemic side effects 1, 3
  • Beta-adrenergic antagonists, such as timolol, can reduce IOP by 15-25%, but are contraindicated in patients with asthma, COPD, or bradycardia 1, 3
  • Alpha-2 adrenergic agonists, such as brimonidine, can reduce IOP by 15-25%, but may cause ocular allergic reactions 2

Target IOP Considerations

  • The target IOP range should be reduced by at least 20-30% from baseline, with an initial target IOP range of 21-24 mmHg for a patient with an IOP of 30 mmHg 2, 5
  • Regular monitoring of IOP, optic nerve structure, and visual fields is essential to assess treatment efficacy 1, 3

Special Considerations

  • Patients with diabetes and hypertension can be treated with prostaglandin analogs, which have minimal systemic effects 2, 3
  • A family history of glaucoma indicates a higher risk of progression, supporting aggressive initial treatment 2
  • High baseline IOP requires effective pressure reduction, with prostaglandin analogs providing the greatest IOP-lowering effect 2, 4

Common Pitfalls to Avoid

  • Poor medication adherence can be improved with once-daily dosing of prostaglandin analogs 2, 6
  • Ignoring systemic comorbidities, such as cardiovascular or respiratory conditions, can lead to inadequate treatment with beta-blockers 3
  • Inadequate follow-up can lead to disease progression, emphasizing the importance of regular monitoring 1, 3

If Initial Treatment is Inadequate

  • Adding a second medication from a different class or considering fixed-combination therapy can improve treatment outcomes 6
  • Evaluating for laser trabeculoplasty as an alternative or adjunctive therapy can be considered if initial treatment is inadequate 1

Initial Management of Primary Open‑Angle Glaucoma: First‑Line Therapy and Target IOP

First‑Line Pharmacologic Therapy

  • Initiate treatment immediately with a prostaglandin analog (e.g., latanoprost, bimatoprost, or travoprost) as monotherapy, aiming for a 20–30 % reduction in intraocular pressure (IOP) from the baseline measurement. 7

Target IOP Setting

  • Set the initial target IOP at 20–30 % below the baseline IOP for all patients with primary open‑angle glaucoma, including those with normal‑tension disease, because any IOP lowering confers benefit. 7, 8
  • If disease progression is observed despite achieving the initial target IOP, lower the target IOP further. 9, 10

Baseline Documentation Requirements

  • Perform gonioscopy at the initial visit to confirm open anterior chamber angles and to exclude secondary causes of glaucoma. 9, 10
  • Document optic nerve head and retinal nerve fiber layer (RNFL) status using both clinical examination and imaging modalities such as optical coherence tomography (OCT) or stereoscopic photography. 7, 8
  • Obtain baseline visual field testing with standard automated perimetry to establish functional status. 9, 10
  • Specifically assess for disc rim notching at the inferior/superior poles, RNFL thinning, optic disc hemorrhages, beta‑zone parapapillary atrophy, and inter‑eye asymmetry. 7, 9

Monitoring and Follow‑Up

  • Reassess IOP, optic nerve structure, and visual fields at regular intervals to detect any progression of disease. 9, 10
  • If any structural or functional deterioration occurs while the initial target IOP is being met, adjust the target IOP downward. 9, 10

Critical Clinical Pitfalls

  • Do not delay initiation of therapy while awaiting additional testing; early treatment prevents visual disability. 7, 8
  • Do not assume that a normal IOP measurement excludes glaucoma, as approximately 40 % of primary open‑angle glaucoma patients present with IOP within the normal range. 9, 10
  • Do not omit patient education regarding the chronic, progressive nature of glaucoma and the necessity for lifelong treatment and monitoring. 10

Evidence‑Based Management of Primary Open‑Angle Glaucoma

First‑Line Pharmacologic Therapy

  • Prostaglandin analogs (e.g., latanoprost, bimatoprost, travoprost) are the definitive first‑line agents for lowering intraocular pressure (IOP) in primary open‑angle glaucoma, achieving a mean IOP reduction of 20–35 % (approximately 4.8–5.6 mm Hg at 3 months) and are administered once daily, which improves patient adherence and offers favorable tolerability with minimal systemic side effects. Strong guideline recommendation (American Academy of Ophthalmology). 11

Alternative Medication Classes (when prostaglandins are unsuitable)

  • Beta‑adrenergic antagonists (e.g., timolol, betaxolol) lower IOP by 15–25 % but are contraindicated in patients with asthma, chronic obstructive pulmonary disease, or bradycardia. Moderate evidence (AAO guideline). 11
  • Alpha‑2 adrenergic agonists (e.g., brimonidine) provide a 15–25 % IOP reduction; ocular allergic reactions may occur. Moderate evidence. 11
  • Carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide) achieve a 15–20 % IOP decrease. Moderate evidence. 11
  • Rho‑kinase inhibitors (e.g., netarsudil) produce a 10–20 % IOP reduction. Moderate evidence. 11

Established Treatment Algorithm

  • Step 1 – Initiate prostaglandin analog monotherapy aiming for a 20–30 % reduction from baseline IOP. Strong evidence (AAO guideline). 11
  • Step 2 – Add a second‑line agent from a different class (beta‑blocker, alpha‑agonist, or carbonic anhydrase inhibitor) if target IOP is not reached. Strong evidence. [11][12]
  • Step 3 – Consider laser trabeculoplasty as an alternative or adjunctive option when medical therapy is insufficient or not tolerated. Strong evidence. [13][14]
  • Step 4 – Proceed to surgical intervention (e.g., trabeculectomy, tube shunt) if medical and laser treatments fail to control IOP. Strong evidence. 13

Monitoring and Follow‑Up

  • Perform IOP reassessment 2–4 weeks after therapy initiation to verify adequate pressure reduction. Standard practice (AAO).
  • Conduct regular monitoring of IOP, optic‑nerve structure (optical coherence tomography or photography), and visual fields to detect disease progression. Strong evidence. 13

DMSO Is Not a Therapeutic Option for Glaucoma

  • No clinical guidelines, FDA approvals, or high‑quality evidence support the use of dimethyl sulfoxide (DMSO) for primary open‑angle glaucoma; the American Academy of Ophthalmology guidelines make no mention of DMSO as a treatment. Absence of evidence. [13][11][15][14]
  • The only documented ophthalmic role for DMSO in the cited literature is as a plasticizer in experimental drug‑delivery films, serving solely as a vehicle to enhance drug release, not as an active therapeutic agent. Experimental context only.

All facts are derived from cited references and reflect the current evidence‑based recommendations of the American Academy of Ophthalmology.

REFERENCES

← Return to Home